GX Acquisition Corp. Announces Shareholder Approval of Extension Proposal New York, New York

GX Acquisition Corp. Announces Shareholder Approval

of Extension Proposal

New York, New York - May 14, 2021 -

GX Acquisition Corp. ("GX") (NASDAQ: GXGX), a publicly-traded special purpose acquisition company, announced today that its

stockholders have voted to approve an amendment to GX's amended and restated certificate of incorporation to extend the date by

which GX must effectuate its initial business combination from May 23, 2021 to July 31, 2021. As previously disclosed, on January 8, 2021,

GX entered into a Merger Agreement and Plan of Reorganization (the "Merger Agreement") with Celularity Inc. ("Celularity"),

Alpha First Merger Sub, Inc. and Alpha Second Merger Sub, LLC. Upon the terms and subject to the conditions of the Merger Agreement, Celularity

will become a wholly owned subsidiary of GX. GX and Celularity are continuing to work together to address comments from the staff of the

U.S. Securities and Exchange Commission ("SEC") on the proxy statement/prospectus filed in connection with the transaction

and to satisfy the various closing conditions to the consummation of the initial business combination.

GX issued the following statement:

"On behalf of the GX Board of Directors,

I would like to thank our stockholders for their support of this transaction. We look forward to working with Celularity to complete the

merger," said Dean C. Kehler, Co-CEO of GX and Co-Chairman of GX's Board of Directors."

GX has filed today the voting results, as tabulated

by an independent inspector of elections, on a Form 8-K with the SEC.

GX is a blank check company incorporated in Delaware

for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination

with one or more businesses or entities. GX is led by Jay R. Bloom and Dean C. Kehler, who serve as Managing Partners of Trimaran Capital

Additional Information and Where to Find It

GX has filed a registration Statement with the

SEC on Form S-4 (the "Registration Statement"), which includes a preliminary proxy statement to be distributed to holders

of GX's common stock in connection with GX's solicitation of proxies for the vote by GX's stockholders with respect

to a proposed business combination (the "Celularity Business Combination") between GX and Celularity and other matters as

described in the Registration Statement, and a prospectus relating to the offer of the securities to be issued to Celularity's

stockholders in connection with the Celularity Business Combination. After the Registration Statement has been declared effective, GX

will mail a definitive proxy statement and other relevant documents to its stockholders as of the record date established for voting

on the Celularity Business Combination and the other proposals regarding the Celularity Business Combination set forth in the Registration

Statement. GX's stockholders and other interested persons are advised to read the Registration Statement, including the

preliminary proxy statement / prospectus contained therein, and any amendments thereto and, once available, the definitive proxy statement

/ prospectus, in connection with GX's solicitation of proxies for its special meeting of stockholders to be held to approve, among

other things, the Celularity Business Combination, because these documents will contain important information about GX, Celularity and

the Celularity Business Combination. Stockholders may also obtain a copy of the preliminary proxy statement/prospectus or, once available,

the definitive proxy statement/prospectus, as well as other documents filed with the SEC regarding the Celularity Business Combination

and other documents filed with the SEC by GX, without charge, at the SEC's website located at www.sec.gov or by directing a request

to GX Acquisition Corp., 1325 Avenue of the Americas, 25th Floor, New York, NY 10019.

Participants in the Solicitation

GX and its directors

and officers may be deemed participants in the solicitation of proxies of GX's stockholders in connection with the Celularity Business

Combination. GX's stockholders and other interested persons may obtain, without charge, more detailed information regarding the

directors and officers of GX in GX's Annual Report on Form 10-K for the fiscal year ended December 31, 2020,

which was filed with the SEC on March 4, 2021, GX's Definitive Proxy Statement on Schedule 14A, which was filed with the SEC

on December 4, 2020, the Registration Statement, which was initially filed with the SEC on January 25, 2021 and amended on March 29, 2021

and April 23, 2021, including the preliminary proxy statement/prospectus contained therein, and GX's Definitive Proxy Statement

on Schedule 14A, which was filed with the SEC on April 14, 2021.

Information regarding the persons who may, under

SEC rules, be deemed participants in the solicitation of proxies of GX's stockholders in connection with the Celularity Business

Combination and other matters to be voted upon at the special meeting will be set forth in the registration statement for the Celularity

Business Combination. Additional information regarding the interests of participants in the solicitation of proxies in connection with

the Celularity Business Combination is included in the Registration Statement.

This communication is not a proxy statement or

solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall

not constitute an offer to sell or a solicitation of an offer to buy the securities of Celularity, the combined company or GX, nor shall

there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior

to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except

by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance

with applicable law.

Forward Looking Statements

This communication contains, or incorporates by

reference, "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking

statements may include, but are not limited to, statements regarding GX's, GX's management team's, Celularity's

and Celularity's management team's expectations, hopes, beliefs, intentions or strategies regarding the future. In addition,

any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying

assumptions, are forward-looking statements. The words "anticipate," "believe," "can," "contemplate,"

"continue," "could," "estimate," "expect," "forecast," "intends,"

"may," "might," "outlook," "plan," "possible," "potential," "predict,"

"project," "seek," "should," "strive," "target," "will," "would"

and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not

forward-looking. Forward-looking statements in this communication may include, for example: (i) the ability to consummate the Celularity

Business Combination, (ii) the expected benefits of the Celularity Business Combination; (iii) the financial and business performance

of Celularity, (iv) the inability to complete the PIPE Investment; (v) the success and timing of Celularity's cellular therapeutic

development activities and initiating clinical trials; (vi) the success and timing of Celularity's planned clinical trials; (vii)

Celularity's ability to obtain and maintain regulatory approval of any of Celularity's therapeutic candidates; (viii) Celularity's

plans to research, discover and develop additional therapeutic candidates, including by leveraging genetic engineering and other technologies

and expanding into additional indications; (ix) Celularity's ability to expand its manufacturing capabilities, and to manufacture

Celularity's therapeutic candidates and scale production; (x) Celularity's ability to meet certain milestones; (xi) changes

in Celularity's strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans;

(xii) the implementation, market acceptance and success of Celularity's business model; (xiii) developments and projections relating

to Celularity's competitors and industry; (xiv) the impact of health epidemics, including the COVID-19 pandemic, on Celularity's

business and the actions Celularity may take in response thereto; (xv) Celularity's expectations regarding its ability to obtain

and maintain intellectual property protection and not infringe on the rights of others; (xvi) expectations regarding the time during which

GX will be an emerging growth company under the JOBS Act; (xvii) Celularity's future capital requirements and sources and uses of

cash; (xviii) Celularity's ability to obtain funding for its operations; (xix) Celularity's business, expansion plans and

opportunities; and (xx) the outcome of any known and unknown litigation and regulatory proceedings. These forward-looking statements are

based on information available as of the date of this communication, and current expectations, forecasts and assumptions, and involve

a number of judgments, risks and uncertainties. These risks and uncertainties may be amplified by the COVID- 19 pandemic, which has caused

significant economic uncertainty. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ

materially from the results implied by these forward-looking statements. There may be additional risks that neither GX nor Celularity

presently know, or that GX or Celularity currently believe are immaterial, that could also cause actual results to differ from those contained

in the forward-looking statements. In addition, forward-looking statements reflect GX's and Celularity's expectations, plans,

or forecasts of future events and views as of the date of this communication. GX and Celularity anticipate that subsequent events and

developments will cause GX's and Celularity's assessments to change. Accordingly, forward-looking statements should not be

relied upon as representing GX's or Celularity's views as of any subsequent date, and GX does not undertake any obligation

to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information,

future events or otherwise, except as may be required under applicable securities laws. Additional risks and uncertainties are identified

and discussed in GX's reports filed with the SEC and available at the SEC's website at http://www.sec.gov.